Percentage of patients aged 18 years and older with a new diagnosis or recurrent episode of major depressive disorder (MDD) with evidence that they met the DSM-IV-TR criteria for MDD AND for whom there is an assessment of depression severity during the visit in which a new diagnosis or recurrent episode was identified
To ensure that all members diagnosed with HIV receive at least annual testing for CD4 and at least biannual HIV RNA levels to monitor for disease activity.
Percentage of intensive care patients with central lines for whom all
elements of the central line bundle are documented and in place.
The central line bundle elements include:
•Hand hygiene
•Maximal barrier precautions upon insertion
•Chlorhexidine skin antisepsis
•Optimal catheter site selection, with avoidance of the femoral vein for central venous access in patients 18 years and older
•Daily review of line necessity with prompt removal of unnecessary lines
The percentage of adult patients with chronic liver disease who have received a hepatitis A vaccine
Percent of patients who were screened for depression (using a standardized depression screening tool) at start or resumption of home health care
The percentage of patients with in the overall and high risk population with gastroesophogeal reflux disease (GERD) with alarm symptoms who have had an upper gastrointestinal study. (2 separate Denominators)
The proportion of patients discharged from a hospital-based inpatient psychiatric setting on two or more antipsychotic medications.
The proportion of patients discharged from a hospital-based inpatient psychiatric setting with a post discharge continuing care plan created.
The proportion of patients discharged from a hospital-based inpatient psychiatric setting with a complete post discharge continuing care plan, all the components of which are transmitted to the next level of care provider upon discharge.
Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who were prescribed at a minimum peginterferon and ribavirin therapy within the 12 month reporting period